Literature DB >> 8896542

Costs and benefits of routine varicella vaccination in German children.

P Beutels1, R Clara, G Tormans, E Van Doorslaer, P Van Damme.   

Abstract

This study assessed the costs and benefits of introducing routine varicella vaccination to healthy children in Germany. Three vaccination strategies were compared with that of no prevention: vaccination of all 15-month-old children: vaccination of susceptible 12-year-olds (adolescent); and a combination of strategies (children including catch-up). From a purely economic viewpoint, the adeolescent strategy was optimal: It was the only one that resulted in net direct cost savings. However, since this strategy may be less acceptable from a medical or organizational point of view and because total net savings were the highest, a second option was to begin immunization starting with the 15-month-old children and to use the catch-up strategy for 11 years (total benefit-to-cost ratio (BCR), 4.72:1; cost-effectiveness ratio (CER), DM 6915 per life-year saved) and from year 12 on to use the first strategy (BCR, 4.60:1; CER, DM 19,735 per life-year saved).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8896542     DOI: 10.1093/infdis/174.supplement_3.s335

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Varicella vaccination--a critical review of the evidence.

Authors:  S A Skull; E E Wang
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

2.  Varicella vaccination in England and Wales: cost-utility analysis.

Authors:  M Brisson; W J Edmunds
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

3.  Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations.

Authors:  M J Postma; J M Bos; R Welte; R de Groot; W Luytjes; H C Rümke; P Beutels
Journal:  Eur J Health Econ       Date:  2004-02

4.  Economic evaluation of vaccination.

Authors:  P Van Damme; P Beutels
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 5.  Economic evaluations of varicella vaccination programmes: a review of the literature.

Authors:  Nancy Thiry; Philippe Beutels; Pierre Van Damme; Eddy Van Doorslaer
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 6.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

7.  Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?

Authors:  Joke Bilcke; Albert Jan van Hoek; Philippe Beutels
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

8.  Varicella vaccination in Italy : an economic evaluation of different scenarios.

Authors:  Laurent Coudeville; Alain Brunot; Carlo Giaquinto; Carlo Lucioni; Benoit Dervaux
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Reactogenicity to a live attenuated varicella vaccine in Canadian children.

Authors:  F Diaz-Mitoma; S A Halperin; D Scheifele
Journal:  Can J Infect Dis       Date:  2000-03

10.  Burden of chickenpox on families: A study in Quebec.

Authors:  P De Wals; M Blackburn; M Guay; G Bravo; D Blanchette; M Douville-Fradet
Journal:  Can J Infect Dis       Date:  2001-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.